TBPH
Theravance Biopharma, Inc.Company with tickers: TBPH
CIK
1583107
CUSIP
G8807B106
Shares Outstanding
51,553,005
13F Activity (30d)
121 filings
117 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $17,699,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $27,182,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $5,829,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-9,483,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-4,933,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.10 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.10 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |